Silence Therapeutics Q1 Collaboration Revenue £12.4M, Up £1M YoY; Cash Position £152.8M
Portfolio Pulse from Benzinga Newsdesk
Silence Therapeutics reported Q1 collaboration revenue of £12.4M, an increase of £1M year-over-year. The company's cash position stands at £152.8M.
May 16, 2024 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silence Therapeutics reported Q1 collaboration revenue of £12.4M, an increase of £1M year-over-year. The company's cash position stands at £152.8M, indicating strong financial health.
The increase in collaboration revenue and strong cash position are positive indicators of the company's financial health, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100